BioNTech and BMS Reveal Promising Interim Results for Pumitamig in ES‑SCLC
CompanyDrug

BioNTech and BMS Reveal Promising Interim Results for Pumitamig in ES‑SCLC

Summit Therapeutics Presents 2025 HARMONi Study Results at World Lung Cancer Conference
CompanyDrug

Summit Therapeutics Presents 2025 HARMONi Study Results at World Lung Cancer Conference

Guangzhou’s Bio‑Thera Solutions Secures $5.4 Million Milestone from Intas Pharma
Company

Guangzhou’s Bio‑Thera Solutions Secures $5.4 Million Milestone from Intas Pharma

FDA Launches Aggressive Campaign to Curb Misleading Drug Advertisements
CompanyPolicy / Regulatory

FDA Launches Aggressive Campaign to Curb Misleading Drug Advertisements

MSD scrapes £1 billion UK expansion, shifts life‑science research to the US
Company

MSD scrapes £1 billion UK expansion, shifts life‑science research to the US

FibroX Therapeutics Secures IND Approval for FibroCell in Lumbar Disc Degeneration
CompanyDrug

FibroX Therapeutics Secures IND Approval for FibroCell in Lumbar Disc Degeneration

NMPA Unveils 30‑Working‑Day Pathway to Accelerate Innovative Drug Trials
DrugPolicy / Regulatory

NMPA Unveils 30‑Working‑Day Pathway to Accelerate Innovative Drug Trials

Genrix Bio Secures NMPA Approval for GR1803 Bispecific Antibody in Systemic Lupus Erythematosus
CompanyDrug

Genrix Bio Secures NMPA Approval for GR1803 Bispecific Antibody in Systemic Lupus Erythematosus

GenFleet Therapeutics Surges onto Hong Kong Main Board, Raising HK$1.58 B
CompanyDeals

GenFleet Therapeutics Surges onto Hong Kong Main Board, Raising HK$1.58 B

Remedium Bio Teams Up With Eli Lilly to Push Gene‑Therapy Frontiers for Diabetes and Obesity
CompanyDeals

Remedium Bio Teams Up With Eli Lilly to Push Gene‑Therapy Frontiers for Diabetes and Obesity

YolTech Raises 300 Million Yuan Series B, Pushing In‑Vivo Gene‑Editing to the Forefront
CompanyDeals

YolTech Raises 300 Million Yuan Series B, Pushing In‑Vivo Gene‑Editing to the Forefront

Novartis Secures Tabrecta Approval in China for METex14 NSCLC
CompanyDrug

Novartis Secures Tabrecta Approval in China for METex14 NSCLC